David A Spencer
Overview
Explore the profile of David A Spencer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goldberg B, Spencer D, Pandey S, Ordonez T, Barnette P, Yu Y, et al.
Proc Natl Acad Sci U S A
. 2023 May;
120(20):e2221247120.
PMID: 37155897
The first clinical efficacy trials of a broadly neutralizing antibody (bNAb) resulted in less benefit than expected and suggested that improvements are needed to prevent HIV infection. While considerable effort...
2.
Spencer D, Goldberg B, Pandey S, Ordonez T, Dufloo J, Barnette P, et al.
Nat Commun
. 2022 Feb;
13(1):662.
PMID: 35115533
Increasingly, antibodies are being used to treat and prevent viral infections. In the context of HIV, efficacy is primarily attributed to dose-dependent neutralization potency and to a lesser extent Fc-mediated...
3.
Hioe C, Li G, Liu X, Tsahouridis O, He X, Funaki M, et al.
PLoS Pathog
. 2022 Jan;
18(1):e1010183.
PMID: 34986207
Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, vaccine efficacy was 31% and the sole primary correlate...
4.
Sarkar S, Spencer D, Barnette P, Pandey S, Sutton W, Basu M, et al.
Front Immunol
. 2021 Nov;
12:757811.
PMID: 34745131
Induction of broadly neutralizing antibodies (bNAbs) is a major goal for HIV vaccine development. HIV envelope glycoprotein (Env)-specific bNAbs isolated from HIV-infected individuals exhibit substantial somatic hypermutation and correlate with...
5.
Goldberg B, Kaku C, Dufloo J, Bruel T, Schwartz O, Spencer D, et al.
mBio
. 2021 Oct;
12(5):e0174321.
PMID: 34634936
The role of the complement system in HIV-1 immunity and pathogenesis is multifaceted, and an improved understanding of complement activities mediated by HIV-1-specific antibodies has the potential to inform and...
6.
Spencer D, Shapiro M, Haigwood N, Hessell A
Front Public Health
. 2021 Jun;
9:690017.
PMID: 34123998
Despite substantial progress in confronting the global HIV-1 epidemic since its inception in the 1980s, better approaches for both treatment and prevention will be necessary to end the epidemic and...
7.
Malherbe D, Vang L, Mendy J, Barnette P, Spencer D, Reed J, et al.
Front Immunol
. 2021 Mar;
11:626464.
PMID: 33658998
Designing immunogens and improving delivery methods eliciting protective immunity is a paramount goal of HIV vaccine development. A comparative vaccine challenge study was performed in rhesus macaques using clade C...
8.
Spencer D, Malherbe D, Vazquez Bernat N, Adori M, Goldberg B, Dambrauskas N, et al.
J Immunol
. 2021 Jan;
206(5):999-1012.
PMID: 33472907
Vaccine efforts to combat HIV are challenged by the global diversity of viral strains and shielding of neutralization epitopes on the viral envelope glycoprotein trimer. Even so, the isolation of...
9.
Malherbe D, Wibmer C, Nonyane M, Reed J, Sather D, Spencer D, et al.
Front Immunol
. 2020 Jun;
11:984.
PMID: 32582155
We report here on HIV-1 immunization results in rabbits and macaques co-immunized with clade C gp160 DNA and gp140 trimeric envelope vaccines, a strategy similar to a recent clinical trial...
10.
Basu M, Piepenbrink M, Francois C, Roche F, Zheng B, Spencer D, et al.
Cell Rep Med
. 2020 Jun;
1(2).
PMID: 32577626
Induction of persistent HIV-1 Envelope (Env) specific antibody (Ab) is a primary goal of HIV vaccine strategies; however, it is unclear whether HIV Env immunization in humans induces bone marrow...